{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:51Z","timestamp":1787988051708,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002966","name":"Sivas Cumhuriyet University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002966","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      This study aims to assess the diagnostic performance of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT parameters for the preoperative prediction of axillary lymph node (ALN) metastasis in Luminal A-type breast cancer patients, and to investigate the net clinical benefit of combining visual analysis with quantitative metrics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively evaluated 279 treatment-naive female patients histopathologically diagnosed with Luminal A type breast cancer who underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT for staging and subsequent ALN sampling between January 2012 and December 2025. Both visual assessment and quantitative parameters\u2014including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor, as well as axillary SUVmax and the axilla-to-primary SUVmax ratio (SUVr)\u2014were analyzed by two nuclear medicine specialists in consensus. Diagnostic performance was measured using ROC analysis and DeLong\u2019s test. The incremental value of the models was evaluated through Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI), while clinical utility was determined via Decision Curve Analysis (DCA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ALN metastasis was confirmed in 152 (54.5%) patients. All quantitative parameters were significantly higher in the metastatic group (p\u2009&lt;\u20090.001). While expert-based visual analysis showed 84.6% accuracy, axillary SUVmax (AUC: 0.881, 95% CI: 0.841\u20130.920) significantly outperformed visual assessment (AUC: 0.851, p\u2009=\u20090.031). At a cutoff of 0.93, axillary SUVmax yielded 83.6% sensitivity and 79.5% specificity. The Combined Model, integrating visual and quantitative data, achieved the highest diagnostic power (AUC: 0.889) and was statistically superior to axillary SUVmax alone (p\u2009=\u20090.022). The incorporation of quantitative data correctly reclassified 29% (NRI) of metastatic patients initially reported as false negatives in visual analysis and improved overall discrimination by 41.4% (IDI). DCA revealed that the combined model offered a higher net clinical benefit than standard surgical approaches within a 20\u201390% risk threshold range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In Luminal A-type breast cancer, objective quantitative 18F-FDG PET\/CT parameters and their derived multiparametric models significantly exceed the diagnostic limitations of conventional visual assessment. By providing high net clinical benefit in the surgical decision-making process, the proposed combined model has the potential to serve as a valuable personalized decision support tool for the management of high-risk patients and the de-escalation of invasive surgery in low-risk cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07986-0","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:37:51Z","timestamp":1781566671000},"page":"6328-6338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic performance of 18F-FDG PET\/CT in the prediction of axillary lymph node metastasis in Luminal A breast cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1683-1776","authenticated-orcid":false,"given":"Kerim","family":"\u015eeker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcsn\u00fc \u00c7a\u011fr\u0131","family":"Gen\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fclay","family":"Ko\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukaddes","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekiye","family":"Hasbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"7986_CR1","doi-asserted-by":"crossref","unstructured":"Sedeta ET, Jobre B, Avezbakiyev B. Breast cancer: Global patterns of incidence, mortality, and trends. J Clin Oncol. 2023;41(16_suppl):10528.","DOI":"10.1200\/JCO.2023.41.16_suppl.10528"},{"key":"7986_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"M Cheang","year":"2009","unstructured":"Cheang M, Chia S, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 Index, HER2 status, and prognosis of patients with Luminal B breast cancer. JNCI J Natl Cancer Inst. 2009;101:736\u201350.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"7986_CR3","doi-asserted-by":"crossref","unstructured":"Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Research: BCR. 2014;16.","DOI":"10.1186\/bcr3679"},{"key":"7986_CR4","doi-asserted-by":"crossref","unstructured":"Chang J, Leung J, Moy L, Ha S, Moon W. Axillary nodal evaluation in breast cancer: state of the art. Radiology. 2020;295(3):500\u2013515.","DOI":"10.1148\/radiol.2020192534"},{"key":"7986_CR5","doi-asserted-by":"crossref","unstructured":"Mousavi-Kiasary S, Bayat M, Abbasvandi F, Khoundabi B, Mousavi F, Akbari A et al. Tumor characteristics and survival rate of axillary metastatic breast cancer patients: a three decades retrospective cohort study. Sci Rep. 2025;15(1):4571.","DOI":"10.1038\/s41598-024-84115-7"},{"key":"7986_CR6","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1245\/s10434-016-5177-4","volume":"23","author":"G Canavese","year":"2016","unstructured":"Canavese G, Bruzzi P, Catturich A, Tomei D, Carli F, Garrone E, et al. Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial. Ann Surg Oncol. 2016;23:2494\u2013500.","journal-title":"Ann Surg Oncol"},{"key":"7986_CR7","doi-asserted-by":"crossref","unstructured":"Magnoni F, Galimberti V, Corso G, Intra M, Sacchini V, Veronesi P. Axillary surgery in breast cancer: An updated historical perspective. Semin Oncol. 2020;47(6):341\u2013352.","DOI":"10.1053\/j.seminoncol.2020.09.001"},{"key":"7986_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.breast.2023.01.002","volume":"67","author":"T Reimer","year":"2023","unstructured":"Reimer T. Omission of axillary sentinel lymph node biopsy in early invasive breast cancer. Breast: Official J Eur Soc Mastology. 2023;67:124\u20138.","journal-title":"Breast: Official J Eur Soc Mastology"},{"key":"7986_CR9","doi-asserted-by":"publisher","first-page":"111775","DOI":"10.1016\/j.ejrad.2024.111775","volume":"181","author":"T Van Nijnatten","year":"2024","unstructured":"Van Nijnatten T, Poplack SP, Wijgers RA, Kilburn-Toppin F, Athanasiou A, Chang JM, Smidt M. Differences in axillary ultrasound protocols among prospective de-escalating axillary surgical staging trials in clinically node negative early breast cancer patients. Eur J Radiol. 2024;181:111775.","journal-title":"Eur J Radiol"},{"key":"7986_CR10","doi-asserted-by":"crossref","unstructured":"Wu T, Long Q, Zeng L, Zhu J, Gao H, Deng Y et al. Axillary lymph node metastasis in breast cancer: from historical axillary surgery to updated advances in the preoperative diagnosis and axillary management. BMC Surg. 2025;25(1):81.","DOI":"10.1186\/s12893-025-02802-2"},{"key":"7986_CR11","doi-asserted-by":"crossref","unstructured":"Groheux D. FDG-PET\/CT for primary staging and detection of recurrence of breast cancer. Seminars in nuclear medicine. 2022.","DOI":"10.1053\/j.semnuclmed.2022.05.001"},{"key":"7986_CR12","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"S Vaz","year":"2024","unstructured":"Vaz S, Woll JPP, Cardoso F, Groheux D, Cook G, Ulaner G, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:2706\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7986_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.52586\/4960","volume":"26 9","author":"J Liu","year":"2021","unstructured":"Liu J, Bian H, Zhang Y, Gao Y, Yin G, Wang Z, et al. Molecular subtype classification of breast cancer using established radiomic signature models based on 18F-FDG PET\/CT images. Front Biosci. 2021;26 9:475\u201384.","journal-title":"Front Biosci"},{"key":"7986_CR14","doi-asserted-by":"crossref","unstructured":"Urso L, Evangelista L, Alongi P, Quartuccio N, Cittanti C, Rambaldi I et al. The value of semiquantitative parameters derived from 18F-FDG PET\/CT for predicting response to neoadjuvant chemotherapy in a cohort of patients with different molecular subtypes of breast cancer. Cancers. 2022;14(23):5869.","DOI":"10.3390\/cancers14235869"},{"key":"7986_CR15","doi-asserted-by":"crossref","unstructured":"Agarwal A, Wehrle C, Satish S, Mahajan P, Kamath S, Koyfman S et al. PET-assessed metabolic tumor volume across the spectrum of solid-organ malignancies: a review of the literature. Biomedicines. 2025;13(1):123.","DOI":"10.3390\/biomedicines13010123"},{"key":"7986_CR16","doi-asserted-by":"crossref","unstructured":"Hirata K, Tamaki N. Quantitative FDG PET assessment for oncology therapy. Cancers. 2021;13(4):869.","DOI":"10.3390\/cancers13040869"},{"key":"7986_CR17","doi-asserted-by":"crossref","unstructured":"Guo B, Tan X-H, Ke Q, Cen H. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis. PLoS ONE. 2019;14(1):e0210224.","DOI":"10.1371\/journal.pone.0210224"},{"key":"7986_CR18","doi-asserted-by":"crossref","unstructured":"Pellegrino S, Fonti R, Morra R, Di Donna E, Servetto A, Bianco R, Del Vecchio S. Prognostic Value of Tumor Dissemination (Dmax) derived from basal 18F-FDG positron emission tomography\/computed tomography in patients with advanced non-small-cell lung cancer. Biomedicines. 2025;13(2):477.","DOI":"10.3390\/biomedicines13020477"},{"key":"7986_CR19","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1002\/hed.26461","volume":"42","author":"J Rijo-Cede\u00f1o","year":"2020","unstructured":"Rijo-Cede\u00f1o J, Mucientes J, Alvarez O, Royuela A, Marcos SS, Romero J, Garc\u00eda-Berrocal J. Metabolic tumor volume and total lesion glycolysis as prognostic factors in head and neck cancer: Systematic review and meta-analysis. Head Neck. 2020;42:3744\u201354.","journal-title":"Head Neck"},{"key":"7986_CR20","doi-asserted-by":"crossref","unstructured":"Hwang A, Rashid S, Shi S, Blew C, Levine M, Saha A. 18F-FDG PET\/CT Semiquantitative and radiomic features for assessing pathologic axillary lymph node status in clinical stage I\u2013III breast cancer patients: a systematic review. Curr Oncol. 2025;32(6):300.","DOI":"10.3390\/curroncol32060300"},{"issue":"8","key":"7986_CR21","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies\u2013improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533\u201346.","journal-title":"Ann Oncol"},{"issue":"9","key":"7986_CR22","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206\u201323.","journal-title":"Ann Oncol"},{"key":"7986_CR23","doi-asserted-by":"crossref","unstructured":"Sayed M, Tawfik A, Mohamadien N. Merits of 18F-FDG PET\/CT metabolic tumor volume for prediction of occult axillary lymph node metastasis in luminal early breast cancer patients with clinical and radiologically negative axilla. Egypt J Radiol Nuclear Med. 2024;55:241.","DOI":"10.1186\/s43055-024-01414-9"},{"key":"7986_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.21873\/invivo.12228","volume":"35","author":"J Kasem","year":"2021","unstructured":"Kasem J, Wazir U, Mokbel K, Sensitivity. Specificity and the diagnostic accuracy of PET\/CT for axillary staging in patients with stage I-III cancer: a systematic review of the literature. Vivo. 2021;35:23\u201330.","journal-title":"Vivo"},{"key":"7986_CR25","doi-asserted-by":"crossref","unstructured":"Zhang X, Liu Y, Luo H, Zhang J. PET\/CT and MRI for identifying axillary lymph node metastases in breast cancer patients: systematic review and meta-analysis. J Magn Reson Imaging. 2020;52(6):1840\u20131851.","DOI":"10.1002\/jmri.27246"},{"key":"7986_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5144\/0256-4947.2025.145","volume":"45","author":"A Gunes","year":"2025","unstructured":"Gunes A, Colapkulu-Akgul N, Akgul C, Unlu I, Cinar S. Axillary staging with 18F-FDG PET\/CT in early breast cancer: impact of tumor subtypes. Ann Saudi Med. 2025;45:145\u201353.","journal-title":"Ann Saudi Med"},{"key":"7986_CR27","doi-asserted-by":"crossref","unstructured":"Cheng J, Ren C, Liu G, Shui R, Zhang Y, Li J, Shao Z. Development of high-resolution dedicated PET-based radiomics machine learning model to predict axillary lymph node status in early-stage breast cancer. Cancers. 2022;14(4):950.","DOI":"10.3390\/cancers14040950"},{"key":"7986_CR28","doi-asserted-by":"crossref","unstructured":"Li Y, Han D, Shen C, Duan X. Construction of a comprehensive predictive model for axillary lymph node metastasis in breast cancer: a retrospective study. BMC Cancer. 2023;23(1):1028.","DOI":"10.1186\/s12885-023-11498-7"},{"key":"7986_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2967\/jnumed.122.264138","volume":"64","author":"J Morawitz","year":"2022","unstructured":"Morawitz J, Sigl B, Rubbert C, Bruckmann N, Dietzel F, H\u00e4berle L, et al. Clinical decision support for axillary lymph node staging in newly diagnosed breast cancer patients based on 18F-FDG PET\/MRI and machine learning. J Nuclear Med. 2022;64:304\u201311.","journal-title":"J Nuclear Med"},{"key":"7986_CR30","doi-asserted-by":"crossref","unstructured":"Romeo V, Kapetas P, Clauser P, Rasul S, Cuocolo R, Caruso M et al. Simultaneous 18F-FDG PET\/MRI radiomics and machine learning analysis of the primary breast tumor for the preoperative prediction of axillary lymph node status in breast cancer. Cancers. 2023;15(20):5088.","DOI":"10.3390\/cancers15205088"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07986-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:40Z","timestamp":1787986840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07986-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7986"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07986-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval was obtained from the local ethics committee. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}